AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03506945 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bibliotherapy
Description: Provide educational material on coping strategies pertinent to caregivers
Study NCT03784469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing body position in bed
Description: The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
Study NCT00040105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zarnestra (R115777)
Description: Starting Dose:~300 mg by mouth (PO) Twice daily
Study NCT00040105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec (Imatinib mesylate)
Description: Starting Dose:~300 mg By Mouth (PO) daily
Study NCT00814398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Embryo Transfer (SET)
Description: A single embryo is transferred during an IVF treatment
Study NCT03855280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APVO101
Description: Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
Study NCT00783250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol + Tiotropium
Description: Salbutamol 400 micrograms + Tiotropium 18 micrograms
Study NCT00783250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Tiotropium
Description: Placebo via MDI + Tiotropium 18 micrograms
Study NCT01952431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Lung Capacity (TLC) testing
Description: Comparison of TLC results
Study NCT01952431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Lung Capacity (TLC) testing
Description: Comparison of TLC results
Study NCT04156425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram+golimumab
Description: Escitalopram will be administered at 10-20 mg/d during the acute phase. Golimumab will be administered at the dose of 50mg every month during the acute phase.
Study NCT04156425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Escitalopram+Calcium Tablet
Description: Escitalopram will be administered at 10-20 mg/d during the acute phase. Calcium tablet will be administered at 2000mg/d during the acute phase.
Study NCT04156425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram will be administered at 10-20 mg/d during the acute phase.
Study NCT01122836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Therapeutic Massage
Study NCT03993340 — intervention group
Intervention type: DEVICE
Intervention: Rescue stenting
Description: The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
Study NCT01949168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)
Study NCT01949168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection
Study NCT01949168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebetol® (ribavirin), 1000/1200mg by mouth daily
Study NCT03763123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevacizumab
Description: Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg
Study NCT03763123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80mg/m2 as a > 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;
Study NCT03763123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: topotecan 4 mg/m2 as a >30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;
Study NCT02707198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kefir
Description: 4 ounces of kefir 3 times a day, with or without food.
Study NCT04198441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressing
Description: Clean wound, fill wound, dress wound
Study NCT05146401 — intervention group
Intervention type: OTHER
Intervention: Plasma fatty acid concentration
Description: Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
Study NCT03059498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral PECS I and II block
Description: A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
Study NCT02727205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine Transdermal System
Study NCT04334005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
Study NCT04334005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
Study NCT03483649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Study NCT03059498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral PECS I and II block
Description: A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.
Study NCT03059498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
Study NCT03483649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Avastin®
Description: US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Study NCT03483649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Avastin®
Description: EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Study NCT03483649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CN-Avastin®
Description: CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Study NCT00845364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Study NCT00845364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo marked PEXSIG
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Study NCT00881296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and carboplatin
Description: Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
Study NCT00881296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
Study NCT04068272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Eyedrop
Study NCT04068272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
Study NCT01249209 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: lifestyle advice
Study NCT02727634 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison cardiac power and cardiac power output at different time points in the perioperative period
Description: The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
Study NCT04006834 — intervention group
Intervention type: OTHER
Intervention: No intervention involved
Description: No intervention involved
Study NCT04565977 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Retrospective chart review
Study NCT02669576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind body medicine day care clinic
Description: Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
Study NCT02669576 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients continue usual care by their practitioner
Study NCT03507972 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: ankle ultrasound
Description: Ankle ultrasound performed during emergencies visit.
Study NCT04059094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162
Description: Inhalation solution
Study NCT04059094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation solution
Study NCT03507972 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Member MRI
Description: Member MRI (without injection of contrast product) performed within 7 days following the trauma
Study NCT02617693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
Study NCT02617693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard antenatal care
Description: Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
Study NCT03876197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem/stromal cells
Description: Autologous adipose-derived mesenchymal stem/stromal cells
Study NCT03876197 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%
Study NCT02628626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Study NCT02628626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Study NCT02628626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical in appearance to the active drug.
Study NCT03457129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perampanel Oral Tablet
Description: Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
Study NCT03457129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel Oral Tablet
Description: Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
Study NCT01335581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-Switched Nd:YAG Laser (RevLite)
Description: Laser treatment added to a microdermabrasion and topical lightening agent regimen
Study NCT01335581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retin-A and microdermabrasion
Description: Microdermabrasion and topical lightening agent regimen
Study NCT01335581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retin-A and microdermabrasion
Description: Microdermabrasion and topical lightening agent regimen
Study NCT03336047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personal activity intelligence
Description: Participants randomized to the PAI intervention will receive a Mio Slice fitness bracelet and asked to install the Mio Pai 2.0 app on their smart phone. This tracks their fitness score based on the PAI algorithm where the goal is to maintain 100 PAI points a week. PAI is earned incrementally based on time spent in three different heart rate zones, low, medium and high intensity. PAI is recorded every day and added to the weekly total and the PAI earned on the same day the previous week is deleted (on Tuesday, the PAI earned the previous Tuesday will disappear).~Participants will be encouraged to maintain 100 PAI during the 8 weeks intervention by telephone messages (sms).
Study NCT03336047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10,000 steps daily
Description: Participants randomized to the 10,000 step intervention will receive a fit bit zip step counter and asked to obtain 10.000 steps per day. Participants will be encouraged to obtain 10.000 steps per day by telephone messages (sms).
Study NCT04013724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group tobacco cessation interventions
Description: Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented.
Study NCT04065906 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIRS neurofeedback
Description: Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
Study NCT04065906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIRS neurofeedback
Description: Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
Study NCT04065906 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate or Tomoxetine
Description: Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
Study NCT03701906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus PS11603 & Bifidobacterium PS10402
Description: Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L.salivarius PS11603 and 1\*10E8 CFU of B.longum PS10402.
Study NCT00396591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4.0 mg/kg administered intravenously (IV) once every 2 weeks
Study NCT03701906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
Study NCT01534091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer with supervision
Study NCT01534091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer without supervision
Study NCT03064360 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
Study NCT03064360 — intervention group
Intervention type: DEVICE
Intervention: Patient Activity
Description: Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
Study NCT02170337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 282
Description: AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
Study NCT03064360 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Symptom and quality of life questionnaire at baseline, and every week following to study completion
Study NCT00525707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tezosentan
Description: tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
Study NCT00525707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tezosentan
Description: tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
Study NCT05070533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual treatment
Description: Participants will receive 7 home visits to implement the program.
Study NCT05070533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Groupal treatment
Description: Subjects will participate in groups of about 8 - 12 to implement the program.
Study NCT00512993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
Study NCT01144923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin and/or Nortriptyline, Physical therapy
Description: Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)
Study NCT01144923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Steroid Injections (ESI)
Description: Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone